

Amendments to the Claims

The following Listing of Claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1-19. (cancelled)

20. (currently amended) A solid composition comprising a plurality of particles, said particles ~~comprising~~ consisting essentially of:

- (a) at least ~~40~~5 wt % of a low-solubility drug having a minimum aqueous solubility at pH of 1-8 of less than 0.5 mg/ml, wherein at least a substantial portion of said drug is amorphous;
- (b) ~~30 to 65~~at least 5 wt % of a poloxamer; and
- (c) at least 5 wt% of a stabilizing polymer selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate and carboxymethyl ethyl cellulose;

wherein said particles consist of a solid solution of said low-solubility drug homogeneously distributed throughout said poloxamer and said stabilizing polymer, and wherein said composition provides a relative degree of improvement in physical stability of at least 1.25 relative to a control composition consisting essentially of the same amounts of drug and poloxamer, but without the stabilizing polymer.

21. (cancelled)

22. (previously presented) The solid composition of claim 20 wherein said particles have a lowest glass transition temperature of at least about 40°C at a relative humidity of less than about 10%.

23. (previously presented) The solid composition of claim 22 wherein the lowest glass-transition temperature of said particles is at least about 45°C at a relative humidity of less than about 5%.

24. (previously presented) The solid composition of claim 22 wherein the lowest glass-transition temperature of said particles is at least about 50°C at a relative humidity of less than about 5%.

25. (previously presented) The solid composition of claims 20 wherein said drug has a glass-transition temperature of at least about 20°C at a relative humidity of less than about 5%.

26. (previously presented) The solid composition of claim 25 wherein said drug has a glass-transition temperature of at least about 30°C at a relative humidity of less than about 5%.

27. (previously presented) The solid composition of claim 20 wherein said poloxamer is selected from the group consisting of poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407.

28. (previously presented) The solid composition of claim 20 wherein said drug is selected from the group consisting of antihypertensives, antianxiety agents, anticlotting agents, anticonvulsants, blood glucose-lowering agents, decongestants, antihistamines, antitussives, antineoplastics, beta blockers, anti-inflammatories, antipsychotic agents, cognitive enhancers, cholesterol-reducing agents, anti-atherosclerotic agents, antiobesity agents, autoimmune disorder agents, anti-impotence agents, antibacterial and antifungal agents, hypnotic agents, anti-Parkinsonism agents, anti-Alzheimer's disease agents, antibiotics, anti-depressants, antiviral agents, glycogen phosphorylase inhibitors, microsomal triglyceride transfer protein inhibitors, and cholesteryl ester transfer protein inhibitors.

29. (previously presented) The solid composition of claim 28 wherein said drug is a hydrophobic drug.

30. (previously presented) The solid composition of claim 29 wherein said drug is selected from the group consisting of N-(1,1-dimethylethyl) decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide (3s, 4aS, 8aS)-monomethanesulfonate, [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, or pharmaceutically acceptable forms thereof.

31. (previously presented) The solid composition of claim 20 wherein said poloxamer is present in a sufficient amount such that said composition, following administration to an *in vivo* or *in vitro* aqueous environment of use, provides concentration enhancement relative to a control composition consisting essentially of a dispersion of said drug and said stabilizing polymer, wherein said concentration enhancement is characterized by at least one of (a) a maximum drug concentration (MDC) in said aqueous environment of use that is at least 1.25-fold that provided by said control composition; and (b) an area under the concentration versus time curve (AUC) in said aqueous environment of use for any period of at least 90 minutes between the time of introduction of said composition into said aqueous environment of use and about 270 minutes following introduction to said aqueous environment of use that is at least 1.25-fold that provided by said control composition.

32. (previously presented) The solid composition of claim 20 wherein said poloxamer is present in a sufficient amount such that said composition, following administration to an *in vivo* environment of use, provides concentration enhancement relative to a control composition consisting essentially of a dispersion of said drug and said stabilizing polymer, wherein said concentration enhancement is characterized by at least one of (a) a maximum concentration in the blood (C_{max}) that is at least 1.25-fold that provided by said control composition; and (b) a relative bioavailability that is at least 1.25 fold relative to said control composition.

33. (previously presented) The solid composition of claim 20 wherein said composition is made by a solvent-based process.

34. (previously presented) The solid composition of claim 33 wherein said solvent-based process is spray drying.

35. (new) The solid composition of claim 1 wherein the amount of said drug in said particles is at least 10 wt%.

36. (new) The solid composition of claim 35 wherein the amount of said drug in said particles is at least 20 wt%.

37. (new) The solid composition of claims 35 and 36 wherein the amount of said poloxamer in said particles is 30 to 65 wt%.